Free Trial

MannKind (MNKD) Competitors

MannKind logo
$5.31 -0.18 (-3.28%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$5.34 +0.04 (+0.66%)
As of 10/24/2025 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MNKD vs. ALKS, LGND, FOLD, CLDX, BCRX, NVAX, OPK, DVAX, INVA, and ZBIO

Should you be buying MannKind stock or one of its competitors? The main competitors of MannKind include Alkermes (ALKS), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), OPKO Health (OPK), Dynavax Technologies (DVAX), Innoviva (INVA), and Zenas BioPharma (ZBIO). These companies are all part of the "biotechnology" industry.

MannKind vs. Its Competitors

Alkermes (NASDAQ:ALKS) and MannKind (NASDAQ:MNKD) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Alkermes has higher revenue and earnings than MannKind. Alkermes is trading at a lower price-to-earnings ratio than MannKind, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alkermes$1.56B3.16$367.07M$2.0814.33
MannKind$301.74M5.40$27.59M$0.1148.27

Alkermes currently has a consensus target price of $42.83, indicating a potential upside of 43.74%. MannKind has a consensus target price of $10.86, indicating a potential upside of 104.47%. Given MannKind's higher possible upside, analysts plainly believe MannKind is more favorable than Alkermes.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alkermes
0 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
3 Strong Buy rating(s)
3.00
MannKind
0 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.89

In the previous week, Alkermes had 15 more articles in the media than MannKind. MarketBeat recorded 19 mentions for Alkermes and 4 mentions for MannKind. MannKind's average media sentiment score of 1.22 beat Alkermes' score of 0.62 indicating that MannKind is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alkermes
6 Very Positive mention(s)
2 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
MannKind
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

95.2% of Alkermes shares are held by institutional investors. Comparatively, 49.5% of MannKind shares are held by institutional investors. 4.4% of Alkermes shares are held by insiders. Comparatively, 2.7% of MannKind shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Alkermes has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500. Comparatively, MannKind has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500.

Alkermes has a net margin of 23.15% compared to MannKind's net margin of 10.87%. Alkermes' return on equity of 24.86% beat MannKind's return on equity.

Company Net Margins Return on Equity Return on Assets
Alkermes23.15% 24.86% 17.14%
MannKind 10.87%-32.60%7.81%

Summary

Alkermes beats MannKind on 12 of the 17 factors compared between the two stocks.

Get MannKind News Delivered to You Automatically

Sign up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MNKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MNKD vs. The Competition

MetricMannKindMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.68B$3.44B$6.23B$10.67B
Dividend YieldN/A2.26%5.71%4.82%
P/E Ratio48.2824.2730.1530.17
Price / Sales5.40489.23587.79130.40
Price / Cash39.5645.5737.0161.44
Price / Book-18.3110.4012.046.60
Net Income$27.59M-$52.62M$3.32B$276.82M
7 Day Performance-2.93%2.09%1.89%2.58%
1 Month Performance-0.38%12.32%7.68%3.76%
1 Year Performance-18.81%14.12%56.01%33.84%

MannKind Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MNKD
MannKind
3.6075 of 5 stars
$5.31
-3.3%
$10.86
+104.5%
-17.5%$1.68B$301.74M48.28400Positive News
ALKS
Alkermes
4.6066 of 5 stars
$30.98
+2.4%
$42.00
+35.6%
+11.0%$5.00B$1.56B14.891,800Trending News
Upcoming Earnings
Analyst Upgrade
Analyst Revision
LGND
Ligand Pharmaceuticals
3.7861 of 5 stars
$186.74
+2.8%
$176.50
-5.5%
+68.5%$3.56B$167.13M-46.6980Positive News
FOLD
Amicus Therapeutics
4.3774 of 5 stars
$8.44
+5.0%
$15.88
+88.1%
-26.3%$2.48B$528.29M-70.33480News Coverage
Analyst Forecast
CLDX
Celldex Therapeutics
1.7898 of 5 stars
$27.67
+3.1%
$43.78
+58.2%
-5.0%$1.78B$7.02M-9.19150News Coverage
Analyst Forecast
Gap Up
BCRX
BioCryst Pharmaceuticals
4.3096 of 5 stars
$6.93
+4.5%
$19.18
+176.8%
-12.0%$1.39B$450.71M-38.50530Analyst Forecast
NVAX
Novavax
4.5823 of 5 stars
$8.79
+8.5%
$9.80
+11.5%
-14.1%$1.32B$682.16M3.861,990Trending News
Analyst Forecast
Analyst Revision
Gap Up
OPK
OPKO Health
4.2832 of 5 stars
$1.53
+0.7%
$2.63
+71.6%
+7.1%$1.21B$713.10M0.002,997News Coverage
DVAX
Dynavax Technologies
4.5495 of 5 stars
$10.06
+2.3%
$24.33
+141.9%
-3.6%$1.15B$277.25M-21.87350News Coverage
Analyst Forecast
INVA
Innoviva
4.5295 of 5 stars
$17.21
-0.3%
$37.60
+118.5%
-10.6%$1.09B$358.71M55.52100Analyst Upgrade
ZBIO
Zenas BioPharma
1.8888 of 5 stars
$26.15
+9.2%
$38.33
+46.6%
N/A$1.01B$5M0.00N/APositive News

Related Companies and Tools


This page (NASDAQ:MNKD) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners